Pediatrix Medical Group (NYSE:MD) Director Sells $216,500.00 in Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Laura Linynsky sold 10,000 shares of Pediatrix Medical Group stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $21.65, for a total transaction of $216,500.00. Following the completion of the transaction, the director owned 32,232 shares of the company’s stock, valued at $697,822.80. This trade represents a 23.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Pediatrix Medical Group Trading Up 0.2%

MD stock opened at $22.65 on Thursday. The business has a fifty day moving average price of $17.63 and a 200 day moving average price of $15.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.80 and a quick ratio of 1.80. Pediatrix Medical Group, Inc. has a fifty-two week low of $11.84 and a fifty-two week high of $22.98. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 17.56 and a beta of 1.20.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.21. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The company had revenue of $492.88 million for the quarter, compared to analyst estimates of $476.45 million. During the same quarter in the previous year, the firm earned $0.44 earnings per share. The business’s revenue was down 3.6% on a year-over-year basis. Analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its holdings in Pediatrix Medical Group by 30.7% during the third quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock worth $69,114,000 after buying an additional 968,553 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pediatrix Medical Group by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,399,778 shares of the company’s stock valued at $56,942,000 after acquiring an additional 81,554 shares during the period. American Century Companies Inc. boosted its stake in Pediatrix Medical Group by 38.9% during the 3rd quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock worth $44,940,000 after acquiring an additional 751,109 shares during the last quarter. Boston Partners grew its holdings in Pediatrix Medical Group by 1.3% during the first quarter. Boston Partners now owns 1,981,889 shares of the company’s stock valued at $27,990,000 after purchasing an additional 25,536 shares during the period. Finally, Invesco Ltd. grew its holdings in Pediatrix Medical Group by 9.3% during the first quarter. Invesco Ltd. now owns 863,269 shares of the company’s stock valued at $12,509,000 after purchasing an additional 73,157 shares during the period. Institutional investors own 97.71% of the company’s stock.

Analyst Ratings Changes

MD has been the topic of several research analyst reports. Truist Financial increased their price target on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a research note on Monday. Wall Street Zen upgraded Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 4th. Weiss Ratings restated a “hold (c)” rating on shares of Pediatrix Medical Group in a research report on Wednesday, October 8th. UBS Group upped their price target on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Finally, Leerink Partners lifted their price objective on Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Pediatrix Medical Group has an average rating of “Hold” and an average target price of $19.80.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.